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The cardiovascular pharmacology of nicotine is complex. Nic-
otine acts on nicotinic cholinergic receptors in neural tissues
and in muscle, as well as in the skin, bronchial tree, endothelial
cells, and vascular smooth muscle. These receptors are physi-
ologically activated by acetylcholine. The pharmacodynamics of
nicotine are complex, as dose-response curves are often biphasic,
and tolerance develops rapidly to many effects of nicotine, with
variable rates and extent of development of tolerance for
different responses (1,2). It is in this context of a complex
pharmacology that one needs to interpret basic science cardio-
vascular research on nicotine and the relevance of such studies
to human smoking and the medicinal use of nicotine.
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The two studies in this issue of the Journal describe novel
effects of nicotine in animals or cell preparations. Heeschen
and co-workers (3) show that nicotine enhances arteriogen-
esis in ischemic rabbit hind limbs. Nicotine was shown to
stimulate the expression of monocyte and endothelial adhe-
sion molecules and to increase the release of monocyte che-
moattractant protein-1 (MCP-1). The result was increased
endothelial cell proliferation and increased monocyte adhesion
and migration across endothelial cells. This work builds on two
other recent studies from the same group of researchers. In one
report, nicotine was shown to stimulate angiogenesis by acting
on endothelial cell alpha-7 nicotinic cholinergic receptors (4).
In another report, increased endothelial cell growth in response
to nicotine in vitro and in a mouse model of hind limb
ischemia was observed (5). Nicotine increased capillary growth
and enhanced tissue perfusion. Also in a mouse model,
nicotine enhanced the growth of lung cancer implants and
stimulated the growth of atherosclerotic plaques. The angio-
genesis effect was found to be mediated by the release of nitric
oxide, prostacyclin, and vascular endothelial growth factor (5).
The study by Suzuki et al. (6) in this issue of the Journal
shows that nicotine inhibits apoptosis of cardiac myocytes
induced by lipopolysaccharide in rats. This study raises the
possibility that nicotine could be protective against myocar-
dial cell necrosis and fibrosis, such as occurs in heart failure.
Both studies raise questions about the possible toxicity and
therapeutic benefit of nicotine.
Concerns about cardiovascular toxicity of nicotine arise in
two areas. The first is the contribution of nicotine to the
pathogenesis of cardiovascular disease that occurs in ciga-
rette smokers. The second concern is toxicity in people who
may be using nicotine as a medication to aid tobacco cessation,
or in the potential use of nicotine (or nicotinic cholinergic
agonist compounds) for medical diseases such as ulcerative
colitis, Alzheimer’s disease, and depression, among others.
Because of the complex dose-response and tolerance
issues, it is not easy to extrapolate basic science studies of
nicotine in animals or cell preparations to the effects of
nicotine in people. For example, Heeschen et al. (5) have
indicated that the mechanism by which nicotine promotes
angiogenesis is via stimulation of endothelial cell production
or release of nitric oxide and/or prostacyclin. The release of
nitric oxide and prostacyclin is known to result in the
dilation of blood vessels and in the reduction of platelet
aggregation, effects generally thought to be protective
against vascular ischemia. Viewed in this context, nicotine
would be thought of as beneficial rather than detrimental to
cardiovascular function. However, some studies in humans
suggest that nicotine does not increase but rather decreases
nitric oxide release (7), quite the opposite of the findings in
mice. A study of nicotine patch use in humans found no
effect on prostacyclin release (8). Thus, it is not at all clear
that the mechanisms by which nicotine promotes angiogen-
esis in mice are operative in humans receiving nicotine.
Mechanistic studies such as those published by Heeschen
and co-workers and by Suzuki are important in elucidating
cardiovascular cholinergic pharmacology and the possible
role of the cholinergic nervous system in the pathogenesis of
cardiovascular disease. However, such studies often focus on
particular pathophysiological processes in susceptible animal
models, rather than the effects of nicotine on a functionally
intact organism over time. Therefore, the effects of nicotine
in people, in doses and dosing routes produced by nicotine
medications, cannot be predicted by research studies in mice
or rabbits. We need long-term clinical observations of
nicotine exposure in people to determine whether nicotine
produces harmful effects in humans.
With respect to the role of nicotine in causing cardiovas-
cular disease, there is a body of evidence in smokeless
tobacco users that is reassuring. Smokeless tobacco delivers
as much nicotine as does regular cigarette smoking, but it
does not expose the user to oxidant gases, carbon monoxide,
and other products in tobacco smoke that are toxic to the
cardiovascular system (9,10). Studies of cardiovascular risk
factors, including inflammatory markers and markers of
platelet activation, suggest that cigarette smoking is injuri-
ous but the use of smokeless tobacco is not (10). Case-
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control studies in Sweden, where snuff use is widespread,
show the expected association between cigarette smoking
and myocardial infarction, but no excess risk of myocardial
infarction in snuff users compared to people who use no
tobacco (11,12). These observations suggest that nicotine
per se is not a substantial cause of cardiovascular disease.
Comparing cigarette smoking and nicotine medications,
it is evident that nicotine is quite safe compared to smoking.
Clinical trials of nicotine therapy to aid smoking cessation
in smokers with cardiovascular disease have shown no
evidence of increased risk (13). In fact, smokers who
continue to smoke but smoke fewer cigarettes while using
nicotine patches, despite higher levels of nicotine in the
blood, demonstrate less ischemia during exercise compared
to before taking nicotine medication (14).
Of course, the possibility exists that long-term use of
nicotine as a medication could have adverse cardiovascular
effects in a nonsmoker. In addition to the effects to enhance
angiogenesis described by Heeschen et al. (3,4), nicotine may
induce endothelial cell dysfunction and possibly induce insulin
resistance, both of which are significant risk factors for cardio-
vascular disease (7,15,16). Nicotine also appears to promote
lipolysis, which could contribute to adverse lipid profiles (17).
Although cardiovascular toxicity has been the major
concern of most nicotine research in the past, the present
studies suggest the possibility that nicotine could have
beneficial effects. Angiogenesis and inhibition of apoptosis
could be useful in preserving myocardial function in patients
with ischemic heart disease and other types of myocardial
injury. However, studies of smokers show that cigarette
smoking is a major risk factor for the progression of
ischemic heart disease and of congestive heart failure (18).
Thus, evidence of a beneficial effect of nicotine in smokers
is presently lacking. Of course, numerous other potential
cardiovascular toxins in cigarette smoke could explain dete-
rioration in smokers despite potential beneficial effects of
nicotine per se, so the therapeutic potential for nicotine in
cardiovascular disease remains an open question.
In summary, nicotine has a very complex pharmacology.
This is because nicotinic cholinergic receptors perform
many functions, with different levels of activity and distri-
bution in different parts of the body, and different responses
depending on dose and duration of acetylcholine exposure.
Nicotine activates multiple neurohormonal systems that can
have additive or opposing effects. For drug development,
one would like the most specific drug effects possible, and
perhaps nicotinic cholinergic receptor subtype-specific ago-
nists could be developed that have beneficial cardiovascular
effects without having adverse effects on other systems.
With respect to nicotine toxicity, only human studies in
which the various interacting effects of nicotinic receptor
stimulation are in play can determine whether nicotine
produces cardiovascular harm or benefit in people.
Finally, considering the risks and benefits of nicotine,
even if the concerns about toxicity related to arteriogenesis
raised by Heeschen et al. are valid, this would not diminish
the overwhelming benefit of nicotine medications to aid
cessation in smokers. Cigarette smoke delivers not only nico-
tine at high doses but also a myriad of other toxins that damage
blood vessels and cause cancer. The use of nicotine to stop
smoking or to reduce smoking in someone who would other-
wise not quit is unquestionably safer than continued smoking.
Basic scientific findings regarding the cardiovascular toxicity of
nicotine should not dissuade health providers or patients from
using nicotine to treat tobacco dependence, even in smokers
with known cardiovascular disease.
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